The Cardio Vascular Clinical Trialists Forum (CVCT) serves as a unique think tank, focusing on the latest critical trials in the fields of CardioVascular, CardioRenal, and Cardiometabolic health. It provides a platform for authoritative stakeholders to spend hours delving into individual trials, examining them both individually and in context. The forum aims to foster collaboration, brainstorming, and knowledge-sharing among key clinical trial players.
Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD
November 12, 2026
NEJM publication and AASLD presentation reports that 79% of treated participants with MASLD and available measurements achieved normal liver fat levels at Week 24 after a single dose of CIDEBsiRNA, alongside improvements in markers of liver injury.
Richmond Pharmacology is excited to join the AHA Scientific Sessions 2026 in 14–16 November 2026, on 14–16 November 2026, hosted by the American Heart Association.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
